TheEdgeResearch
Home / Stocks / ARGX

argenx SE (ARGX)

NASDAQ Healthcare Biotechnology
$925.70 ▼ -1.73%
Market Cap
$58.21B
Sector
Healthcare
Industry
Biotechnology
Beta
-0.02
52-Wk Range
661.85-1072.75
CEO
Karen Massey
Country
NL
Currency
USD

argenx SE operates in the Biotechnology industry of the Healthcare sector, headquartered in Amsterdam, NH, NL. The stock last traded at $925.70, down 1.73% on the session, giving a market capitalisation of $58.21B. On trailing twelve-month figures it carries a trailing P/E of 43.98, a net margin of 29.6%. Its beta of -0.02 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
43.98
Price / Sales
13.14
Price / Book
6.97
EV / EBITDA
39.93
Gross margin
90.5%
Operating margin
29.3%
Net margin
29.6%
Return on equity
—
Debt / equity
0.01
Current ratio
5.12
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
1,863
IPO date
2017-05-18
Headquarters
Amsterdam, NH, NL
About argenx SE

argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III trials for several indications, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Furthermore, efgartigimod is progressing through Phase II/III clinical trials for bullous pemphigoid and idiopathic inflammatory myopathy, with its subcutaneous ENHANZE formulation also undergoing preclinical assessment. Beyond its lead product, argenx SE maintains an active pipeline of immunology-focused programs. This includes cusatuzumab, targeted at hematological cancers and high-risk myelodysplastic syndromes (MDS); ARGX-119, an antibody designed to inhibit muscle-specific tyrosine kinase; ARGX-117, slated for severe autoimmune disorders; ARGX-118, aimed at mitigating airway inflammation; and ARGX-120, another candidate for the treatment of autoimmune diseases. The firm also engages in collaborations for additional investigational products, such as ARGX-115 for cancer therapy, ARGX-112 which targets the interleukin-22 receptor, and ARGX-114, an antibody engineered to block the MET receptor. argenx SE has forged strategic alliances with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S. It also holds numerous collaboration and licensing agreements with partners including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., the University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. Established in 2008, argenx SE is headquartered in Breda, the Netherlands.

Comparable companies

argenx SE is most often compared with the following Healthcare names:

AMGNBIIBINCYTGTX
More research on ARGX
ARGX technical analysis ARGX TheEdge Score Compare against peers
Open full interactive analysis & DCF →